Rhythm Biosciences Limited (FRA:0RY)

Market Cap	14.43M -15.8%
Revenue (ttm)	1.05M -47.7%
Net Income	-3.59M
EPS	-0.01
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	700
Open	0.0405
Previous Close	0.0400
Day's Range	0.0405 - 0.0405
52-Week Range	0.0390 - 0.1440
Beta	n/a
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 3, 2026

About Rhythm Biosciences

Rhythm Biosciences Limited, a medical diagnostics company, develops and commercialises medical diagnostic tests for cancer detection in Australia and the United States. The company offers ColoSTAT, a blood test for the early detection of colorectal cancer; and geneType, a personalized predictive test for predicting risk of chronic disease development. Rhythm Biosciences Limited was incorporated in 2017 and is headquartered in Parkville, Australia.

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 2017
• Country: Australia
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 0RY

Financial Performance

In fiscal year 2026, Rhythm Biosciences's revenue was 1.74 million, a decrease of -47.67% compared to the previous year's 3.33 million. Losses were -5.93 million, 54.9% more than in 2025.

Financial numbers in AUD

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Oct 26, 2026

Data Sources Report a data error